T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.82B |
| 2 |
Sea Limited
SE
|
+$1.38B |
| 3 |
Cisco
CSCO
|
+$1.16B |
| 4 |
Netflix
NFLX
|
+$1.14B |
| 5 |
Ingersoll Rand
IR
|
+$1.03B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.54B |
| 2 |
Amazon
AMZN
|
+$1.75B |
| 3 |
Amphenol
APH
|
+$1.65B |
| 4 |
KLA
KLAC
|
+$1.5B |
| 5 |
Xcel Energy
XEL
|
+$1.38B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.6% |
| 2 | Financials | 11.17% |
| 3 | Healthcare | 11.1% |
| 4 | Communication Services | 10.25% |
| 5 | Consumer Discretionary | 10.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2851
TaskUs
TASK
$506M
| $190K | ﹤0.01% |
28,207
| – | – |
|
2852
Tonix Pharmaceuticals
TNXP
$157M
| $190K | ﹤0.01% |
13,816
+2,883
| +26% | +$44.4K |
|
2853
C4 Therapeutics
CCCC
$376M
| $189K | ﹤0.01% |
71,546
+59,146
| +477% | +$139K |
|
2854
Kelly Services Class A
KELYA
$526M
| $189K | ﹤0.01% |
21,338
+4,650
| +28% | +$44.3K |
|
2855
Sanara MedTech
SMTI
$234M
| $188K | ﹤0.01% |
10,898
+2,200
| +25% | +$45.3K |
|
2856
Standard BioTools
LAB
$326M
| $187K | ﹤0.01% |
202,466
+30,332
| +18% | +$36.7K |
|
|
ACH
2857
Accendra Health
ACH
$240M
| $187K | ﹤0.01% |
81,718
+1,810
| +2% | +$4.17K |
|
2858
Mastech Digital
MHH
$93.1M
| $186K | ﹤0.01% |
32,598
| – | – |
|
2859
Vipshop
VIPS
$6.84B
| $186K | ﹤0.01% |
11,800
-3,900
| -25% | -$66.3K |
|
2860
GrafTech
EAF
$194M
| $185K | ﹤0.01% |
27,188
+3,500
| +15% | +$37K |
|
2861
VTEX
VTEX
$665M
| $185K | ﹤0.01% |
46,159
+13,853
| +43% | +$48.4K |
|
|
TBI
2862
Trueblue
TBI
$234M
| $184K | ﹤0.01% |
46,959
-10,000
| -18% | -$44.4K |
|
|
PINE
2863
Alpine Income Property Trust
PINE
$339M
| $181K | ﹤0.01% |
+10,052
| New | +$187K |
|
2864
Liberty Latin America Class A
LILA
$1.51B
| $179K | ﹤0.01% |
30,389
+7,061
| +30% | +$37.2K |
|
2865
Playtika
PLTK
$1.4B
| $179K | ﹤0.01% |
64,275
| – | – |
|
2866
Radiant Logistics
RLGT
$416M
| $178K | ﹤0.01% |
25,206
+7,426
| +42% | +$52.1K |
|
2867
Perspective Therapeutics
CATX
$332M
| $177K | ﹤0.01% |
42,282
+12,513
| +42% | +$52.9K |
|
2868
OrthoPediatrics
KIDS
$485M
| $177K | ﹤0.01% |
11,147
+505
| +5% | +$8.82K |
|
2869
Rezolute
RZLT
$480M
| $176K | ﹤0.01% |
57,585
+12,497
| +28% | +$37.5K |
|
2870
Design Therapeutics
DSGN
$736M
| $175K | ﹤0.01% |
16,370
+659
| +4% | +$6.67K |
|
2871
ProShares UltraShort Bloomberg Crude Oil
SCO
$585M
| $175K | ﹤0.01% |
+5,250
| New | +$295K |
|
2872
Canterbury Park Holding Corp
CPHC
$80.1M
| $174K | ﹤0.01% |
11,247
| – | – |
|
2873
Barings BDC
BBDC
$862M
| $173K | ﹤0.01% |
20,930
-15,363
| -42% | -$135K |
|
2874
Latham Group
SWIM
$646M
| $173K | ﹤0.01% |
32,172
+8,215
| +34% | +$52.3K |
|
|
NMAX
2875
Newsmax Inc
NMAX
$969M
| $172K | ﹤0.01% |
32,852
+8,178
| +33% | +$55.2K |
|
Similar funds
T. Rowe Price Associates's Q1 2026 Portfolio in Review
As of Q1 2026, T. Rowe Price Associates held 3,202 positions worth $865B, down 6.7% from $927B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
T. Rowe Price Associates's Q1 2026 filing shows 115 new, 2,022 increased, 804 reduced and 71 closed positions. Its largest new stake was Cenovus Energy: 23,907,299 shares worth $634M. The largest sale was Microsoft, an estimated $3.54B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q1 2026 buy was Cenovus Energy: 23,907,299 shares worth $634M.
- T. Rowe Price Associates added most to Advanced Micro Devices in Q1 2026, an estimated $1.82B increase.
- T. Rowe Price Associates's biggest Q1 2026 reduction was Microsoft, cutting an estimated $3.54B.
- T. Rowe Price Associates fully exited CyberArk in Q1 2026, selling an estimated $251M.
- T. Rowe Price Associates's ten largest holdings make up 34% of its $865B portfolio in Q1 2026.
- T. Rowe Price Associates opened 115 new positions and closed 71 in Q1 2026.
- T. Rowe Price Associates's portfolio value fell 6.7% quarter-over-quarter to $865B.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.